Immtech Pharmaceuticals, Inc. (NYSE:IMM)
Industry: Healthcare
Immtech Pharmaceuticals, Inc., formerly Immtech International, Inc., is a pharmaceutical company advancing the development and commercialization of oral drugs to treat infectious diseases and extending its aromatic cation technology platform to the treatment of cancer, diabetes and other diseases. The Company has clinical programs that include new treatments for malaria, Pneumocystis pneumonia (PCP) and African sleeping sickness (trypanosomiasis), and drug development programs for fungal infections and tuberculosis (TB). It holds worldwide patents and patent applications, and licenses and rights to license technology, primarily from a scientific consortium that has granted the Company a worldwide license and rights to commercialize products from, and license rights to, the technology. The scientific consortium includes scientists from The University of North Carolina at Chapel Hill (UNC), Georgia State University (Georgia State), Duke University (Duke University) and Auburn University (Auburn University) (collectively the Scientific Consortium). The Company has two Phase III pivotal human clinical trials and one Phase II clinical trial of DB289 used to treat African sleeping sickness either in progress or planned within 2005 and several more laboratory development programs in progress testing the safety and effectiveness of other compounds in animal models for various indications, including TB and fungal diseases. Immtech Pharmaceuticals, Inc. is able to coordinate the development of simultaneous treatment programs using DB289 by building on the results of its Phase II safety and efficacy trials to initiate a Phase III study in African sleeping sickness, a Phase IIb study in malaria and a Phase III study in PCP. Malaria On November 26, 2003, the Company entered into a testing agreement with The Medicines for Malaria Venture (MMV) and UNC, pursuant to which the Company, with the support of MMV and UNC, is conducting a study of DB289 as a treatment for malaria. The studies to be performed include Phase II and Phase III human clinical trials and drug development activities of DB289 alone and in combination with other anti-malarial drugs, with the goal of obtaining the United States Food and Administration (FDA) or equivalent regulatory approval of a product for the treatment of malaria. Under the terms of the agreement, MMV has committed to advance funds to the Company to pay for human clinical trials and regulatory preparation and filing costs to obtain approval to market DB289 for the treatment of malaria. MMV has agreed pursuant to the terms of the testing agreement to pay to obtain regulatory approvals for DB289 from at least one internationally accepted regulatory agency and at least one malaria-endemic country. In December 2003, Immtech Pharmaceuticals, Inc. reported results of its Phase IIa malaria trial that was conducted in Thailand. The patients who participated in the malaria trial were treated with 100 milligrams capsules of DB289 twice per day for five consecutive days. For purposes of this study, patients were considered to be cured if patients remained free of malaria parasites at 28 days after the start of treatment. All 32 patients cleared the malaria parasite and malaria symptoms disappeared within the treatment period, 50% of the patients cleared the malaria parasite within 24 hours of the first dose. DB289 was well tolerated with no significant adverse side-effects reported. All patients were monitored for 28 days after the start of treatment to ensure that the malaria parasite had been eliminated. Out of the 32 patients in the Phase IIa malaria trial, nine were infected with Plasmodium vivax and 23 were infected with Plasmodium falciparum (the most deadly form of malaria contracted by humans). The P. falciparum patients were treated with DB289 as a monotherapy (not in combination with any other drugs). Of the 23 patients treated for P. falciparum, approximately 96% (22 of 23 patients) eliminated the original malaria parasite (and were considered to be cured). Nine P. vivax patients we
As Of: 10/07 00:00 ET
*Quotes delayed by 20min.
BuyIns.Net Alerts for Symbol IMM
- No BuyIns.Net Alerts Available for IMM
Graphs for IMM
3 Month Graph
6 Month Graph
1 Year Graph
